Literature DB >> 21537015

In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.

Diane M Citron1, Kerin L Tyrrell, Vreni Merriam, Ellie J C Goldstein.   

Abstract

NXL104, a novel β-lactamase inhibitor, was tested at a constant concentration of 4 μg/ml in combination with ceftazidime (CAZ), with and without added metronidazole, against 396 β-lactamase-producing strains of anaerobic bacteria. MIC(50)/MIC(90) values for Bacteroides fragilis and the B. fragilis group were 8/16 and 64/>128 μg/ml, respectively. Although CAZ-NXL104 had limited activity against most anaerobic strains, in combination with metronidazole it shows potential for treating mixed infections involving resistant Enterobacteriaceae and anaerobes.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21537015      PMCID： PMC3122467          DOI： 10.1128/AAC.01682-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Coincidence of bft and cfiA genes in a multi-resistant clinical isolate of Bacteroides fragilis.

Authors:  Gabriella Terhes; Jon S Brazier; József Sóki; Edit Urbán; Elisabeth Nagy
Journal:  J Med Microbiol       Date:  2007-10       Impact factor: 2.472

2.  Genetic determinants for cfxA expression in Bacteroides strains isolated from human infections.

Authors:  Nuria García; Gloria Gutiérrez; María Lorenzo; José E García; Segundo Píriz; Alberto Quesada
Journal:  J Antimicrob Chemother       Date:  2008-09-04       Impact factor: 5.790

3.  In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.

Authors:  Andrea Endimiani; Yuvraj Choudhary; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

4.  Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. isolated from human clinical infections.

Authors:  Yumi A Warren; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 5.  Resistance to beta-lactam antibiotics in Bacteroides spp.

Authors:  R Edwards
Journal:  J Med Microbiol       Date:  1997-12       Impact factor: 2.472

6.  Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey.

Authors:  J Sóki; R Edwards; M Hedberg; H Fang; E Nagy; C E Nord
Journal:  Int J Antimicrob Agents       Date:  2006-11-13       Impact factor: 5.283

7.  Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics.

Authors:  Segundo Píriz; Santiago Vadillo; Alberto Quesada; Jerónimo Criado; Rosario Cerrato; Juan Ayala
Journal:  J Med Microbiol       Date:  2004-03       Impact factor: 2.472

8.  NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Christine Miossec; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2008-08-09       Impact factor: 5.790

Review 9.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

10.  In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Authors:  Thérèse Stachyra; Premavathy Levasseur; Marie-Claude Péchereau; Anne-Marie Girard; Monique Claudon; Christine Miossec; Michael T Black
Journal:  J Antimicrob Chemother       Date:  2009-06-02       Impact factor: 5.790
  10 in total
  19 in total

Review 1.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

2.  Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases.

Authors:  Sushmita D Lahiri; Stefano Mangani; Thomas Durand-Reville; Manuela Benvenuti; Filomena De Luca; Gautam Sanyal; Jean-Denis Docquier
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Authors:  Sherwin K B Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

5.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 6.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

7.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

Review 8.  The β-Lactams Strike Back: Ceftazidime-Avibactam.

Authors:  Evan J Zasowski; Jeffrey M Rybak; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2015-08       Impact factor: 4.705

Review 9.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

Review 10.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.